Hybrid carbon-based materials for gene delivery in cancer therapy.


Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
02 2020
Historique:
received: 11 11 2019
revised: 16 12 2019
accepted: 16 12 2019
pubmed: 22 12 2019
medline: 22 6 2021
entrez: 22 12 2019
Statut: ppublish

Résumé

Accumulation at tumor tissue without any damage to healthy normal tissues is an ultimate goal in cancer therapy. Despite many efforts in the field of cancer therapy, this disease remains as the major reason of mortality all over the world. Gene therapy has introduced great opportunity to fight against cancer disease. It should be noted that still some obstacles limit clinical application of gene delivery approach, which have to be overcome for efficient transportation of therapeutic gene to the site of action. In this regard, carbon nanomaterials and their unique physical and chemical properties such as their capability of DNA protection have attracted much attention in the field of nanomedicine and non-viral carriers for therapeutic genes. Although, negligible solubility of carbon nanomaterials in biological environments has limited their biomedical application but their structural characteristics facilitate their chemical modifications thereby overcoming their solubility problem. Moreover, hybridization of modified carbon materials with different polymers provides more biocompatible and capable systems for gene delivery purposes. In the current review, we summarized hybrid carbon-based materials as non-viral carriers for gene delivery.

Identifiants

pubmed: 31862358
pii: S0168-3659(19)30749-7
doi: 10.1016/j.jconrel.2019.12.030
pii:
doi:

Substances chimiques

Carbon 7440-44-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-175

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Sahar Taghavi (S)

Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Khalil Abnous (K)

Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Seyed Mohammad Taghdisi (SM)

Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Mohammad Ramezani (M)

Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: ramezanim@mums.ac.ir.

Mona Alibolandi (M)

Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: alibolandim@mums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH